On Veterans' Day, Wall Street was indeed All Quiet on the Western Front
, with Dow Industrials
(^DJI) down 0.31, S&P 500 stocks
(^GSPC) up 0.18, and Nasdaq
(^IXIC) off all of 0.61. That would be points, not percent, making it the smallest cumulative move for the major averages since 1989, the year the Coldest War officially concluded with the fall of the wall.
did its level best to enliven proceedings, with yet another trading glitch impacting 216 securities, but overall investors welcomed the boredom after last week’s way too exciting action in equities. While the US was in semi-holiday mode, Europe remained open, alas. On "The Thinker’s" birthday
, the continent’s finance ministers convened again in Brussels for their umpteenth discussion on their debt debacle. To judge by this morning’s 14.14% fall in National Bank of Greece
(NBG), what the EU needs is neither navel gazing nor more talk, but immediate action.
There’s no top-tier economic data due this morning but quarterly earnings continue apace, with retailers increasingly coming to the fore. Aecom Technology
(ACM), Cisco Systems
(CSCO), Dick’s Sporting Goods
(EONGY), Home Depot
(HD), Michael Kors
(KORS), Saks Inc.
(SKS), TJX Companies
(VIVHY), and Vodafone
(VOD) are all due to release results today.
(ANTH): Leerink Swann launches Outperform rated research, and a $3 price target, on the small cap stock.
(NYSE:BERY): The stock is begun with a Buy at Bank of America-Merrill Lynch, Citigroup, Deutsche Bank, Goldman Sachs, and Lazard. Credit Suisse and Robert W. Baird roll out equally upbeat Outperforms, the latter with a $20 price target. Catalysts include an emphasis on balance sheet deleveraging and calibrated growth.
: Credit Suisse assigns Outperforms on Regeneron
(REGN), Seattle Genetics
(SGEN), and Xoma Corp
(FCS): Susquehanna has a fresh Positive on FCS.
(HITT): The name is assigned an Outperform with Wells Fargo.
(KERX): The small cap is covered at an Outperform by Burrill Institutional Research, which issues a $6 price objective. Key product Zerenex, an oral phosphate binder, has demonstrated efficacy across six Phase 2 trials.
(NGD): Credit Suisse covers the commodity company at Outperform.
(PBYI): PBYI is picked up with an Outperform at Cowen & Co.
(RBC): Janney Montgomery Scott resumes Buy rated research, and an $85 price objective, on RBC.
(SDRL): Shares are begun with a Buy at Deutsche Bank.
(See also: Stock Downgrades: Molycorp Can No Longer Be Mollycoddled
and Stock Upgrades: Sherwin-Williams Set to Paint the Town Red
No positions in stocks mentioned.
The information on this website solely reflects the analysis of or opinion about the performance of securities and financial markets by the writers whose articles appear on the site. The views expressed by the writers are not necessarily the views of Minyanville Media, Inc. or members of its management. Nothing contained on the website is intended to constitute a recommendation or advice addressed to an individual investor or category of investors to purchase, sell or hold any security, or to take any action with respect to the prospective movement of the securities markets or to solicit the purchase or sale of any security. Any investment decisions must be made by the reader either individually or in consultation with his or her investment professional. Minyanville writers and staff may trade or hold positions in securities that are discussed in articles appearing on the website. Writers of articles are required to disclose whether they have a position in any stock or fund discussed in an article, but are not permitted to disclose the size or direction of the position. Nothing on this website is intended to solicit business of any kind for a writer's business or fund. Minyanville management and staff as well as contributing writers will not respond to emails or other communications requesting investment advice.
Copyright 2011 Minyanville Media, Inc. All Rights Reserved.